

Ennio Antonio Chiocca

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/87650/publications.pdf>

Version: 2024-02-01

180
papers

10,441
citations

53660

45
h-index

35952

97
g-index

184
all docs

184
docs citations

184
times ranked

13894
citing authors

#	ARTICLE	IF	CITATIONS
1	Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results. <i>Neuro-Oncology</i> , 2022, 24, 101-113.	0.6	38
2	Neurosurgery Research and Education Foundation funding conversion to National Institutes of Health funding. <i>Journal of Neurosurgery</i> , 2022, 136, 287-294.	0.9	2
3	The Evolving Role of Neurosurgical Intervention for Central Nervous System Tumors. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, 63-75.	0.9	1
4	Virotherapy treatment of central nervous system tumors. , 2022, , 55-71.		0
5	Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: An open-label, multi-institutional phase I trial. <i>Neuro-Oncology</i> , 2022, 24, 951-963.	0.6	44
6	Immune Checkpoint Inhibition in GBM Primed with Radiation by Engineered Extracellular Vesicles. <i>ACS Nano</i> , 2022, 16, 1940-1953.	7.3	58
7	Systemic high-dose dexamethasone treatment may modulate the efficacy of intratumoral viral oncolytic immunotherapy in glioblastoma models. , 2022, 10, e003368.		9
8	Advances in local therapy for glioblastoma â€” taking the fight to the tumour. <i>Nature Reviews Neurology</i> , 2022, 18, 221-236.	4.9	106
9	Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making. <i>Neuro-Oncology</i> , 2022, 24, 1140-1149.	0.6	13
10	Agent-based computational modeling of glioblastoma predicts that stromal density is central to oncolytic virus efficacy. <i>IScience</i> , 2022, 25, 104395.	1.9	23
11	Target receptor identification and subsequent treatment of resected brain tumors with encapsulated and engineered allogeneic stem cells. <i>Nature Communications</i> , 2022, 13, 2810.	5.8	10
12	Abstract 6388: The effect of oncolytic virus therapy on neoantigen specific immune responses. <i>Cancer Research</i> , 2022, 82, 6388-6388.	0.4	0
13	Feasibility and conduct of INSIGHT, a platform trial of patients with glioblastoma using Bayesian adaptive randomization.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2012-2012.	0.8	2
14	STING activation promotes robust immune response and NK cellâ€”mediated tumor regression in glioblastoma models. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	44
15	Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma. <i>Clinical Cancer Research</i> , 2021, 27, 276-287.	3.2	100
16	Targeting Glioblastoma Using a Novel Peptide Specific to a Deglycosylated Isoform of Brevican. <i>Advanced Therapeutics</i> , 2021, 4, 2000244.	1.6	11
17	Therapeutic cancer vaccines for pediatric malignancies: advances, challenges, and emerging technologies. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab027.	0.4	13
18	Role of surgery for glioblastoma: response to letters from Dr. Gerritsen and his colleagues and Dr. Vargas Lopez. <i>Neuro-Oncology</i> , 2021, 23, 506-507.	0.6	0

#	ARTICLE	IF	CITATIONS
19	Oncolytic HSV Vectors and Anti-Tumor Immunity. <i>Current Issues in Molecular Biology</i> , 2021, 41, 381-468.	1.0	8
20	Introduction. Gene and viral therapy for glioblastoma multiforme. <i>Neurosurgical Focus</i> , 2021, 50, E1.	1.0	0
21	Oncolytic Virus Therapy Alters the Secretome of Targeted Glioblastoma Cells. <i>Cancers</i> , 2021, 13, 1287.	1.7	8
22	Biographies of international women leaders in neurosurgery. <i>Neurosurgical Focus</i> , 2021, 50, E19.	1.0	5
23	Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. <i>Cell</i> , 2021, 184, 1281-1298.e26.	13.5	210
24	Targeting glioma-initiating cells via the tyrosine metabolic pathway. <i>Journal of Neurosurgery</i> , 2021, 134, 721-732.	0.9	23
25	The 1994 National Cancer Institute's strategy to fund multi-institutional, multidisciplinary consortia to design and conduct early phase clinical trials in patients with high grade gliomas.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2003-2003.	0.8	0
26	Preliminary results of the abemaciclib arm in the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGHt): A phase II platform trial using Bayesian adaptive randomization.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2014-2014.	0.8	10
27	First-in-human CAN-3110 (ICP-34.5 expressing HSV-1 oncolytic virus) in patients with recurrent high-grade glioma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2009-2009.	0.8	3
28	Evolution of the Neurosurgeon's Role in Clinical Trials for Glioblastoma: A Systematic Overview of the Clinicaltrials.gov Database. <i>Neurosurgery</i> , 2021, 89, 196-203.	0.6	2
29	Evaluating the benefit of adaptive randomization in the CC-115 arm of the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGHt): A phase II randomized Bayesian adaptive platform trial in newly diagnosed MGMT unmethylated glioblastoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2006-2006.	0.8	5
30	The Current Landscape of Oncolytic Herpes Simplex Viruses as Novel Therapies for Brain Malignancies. <i>Viruses</i> , 2021, 13, 1158.	1.5	16
31	Cytomegalovirus infection of glioblastoma cells leads to NF- κ B dependent upregulation of the c-MET oncogenic tyrosine kinase. <i>Cancer Letters</i> , 2021, 513, 26-35.	3.2	2
32	Glial and myeloid heterogeneity in the brain tumour microenvironment. <i>Nature Reviews Cancer</i> , 2021, 21, 786-802.	12.8	83
33	CLRM-05. DRUG-RELEASING MICRODEVICES TO PREDICT RESPONSES TO TARGETED THERAPIES IN PATIENTS WITH GLIOMAS. <i>Neuro-Oncology Advances</i> , 2021, 3, iv2-iv2.	0.4	0
34	Unique challenges for glioblastoma immunotherapy" discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. <i>Neuro-Oncology</i> , 2021, 23, 356-375.	0.6	59
35	An oncolytic virus expressing a full-length antibody enhances antitumor innate immune response to glioblastoma. <i>Nature Communications</i> , 2021, 12, 5908.	5.8	56
36	EXTH-61. MODULATION OF THE IL-27 RECEPTOR SIGNALING PATHWAY IN GLIOBLASTOMA AND ONCOLYTIC VIROTHERAPY. <i>Neuro-Oncology</i> , 2021, 23, vi177-vi177.	0.6	0

#	ARTICLE	IF	CITATIONS
37	EXTH-81. STING ACTIVATION PROMOTES ROBUST IMMUNE RESPONSE AND TUMOR REGRESSION IN GLIOBLASTOMA MODELS. <i>Neuro-Oncology</i> , 2021, 23, vi182-vi182.	0.6	0
38	CTNI-05. PRELIMINARY RESULTS OF THE NERATINIB ARM IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II PLATFORM TRIAL USING BAYESIAN ADAPTIVE RANDOMIZATION. <i>Neuro-Oncology</i> , 2021, 23, vi59-vi59.	0.6	4
39	CTIM-20. FINAL RESULTS OF CONTROLLED IL-12 MONOTHERAPY AND IN COMBINATION WITH PD-1 INHIBITOR IN ADULT SUBJECTS WITH RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2021, 23, vi54-vi54.	0.6	4
40	CTNI-40. EVALUATING FEASIBILITY AND EFFICIENCY OF PHASE II ADAPTIVE PLATFORM TRIAL DESIGNS BASED ON THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT) EXPERIENCE. <i>Neuro-Oncology</i> , 2021, 23, vi68-vi69.	0.6	0
41	CTIM-18. LUMINOS-101: INITIAL SAFETY AND TOLERABILITY OF PVSRIPO AND PEMBROLIZUMAB COMBINATION THERAPY IN RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2021, 23, vi53-vi54.	0.6	1
42	CSIG-19. DISRUPTION OF DNA DAMAGE RESPONSE MODULATES THE EFFICACY OF LOCAL IMMUNOTHERAPIES IN EXPERIMENTAL GLIOMA. <i>Neuro-Oncology</i> , 2021, 23, vi37-vi37.	0.6	0
43	IMMU-26. SAFETY AND EFFICACY OF PVSRIPO IN RECURRENT GLIOBLASTOMA: LONG-TERM FOLLOW-UP AND INITIAL MULTICENTER RESULTS. <i>Neuro-Oncology</i> , 2021, 23, vi97-vi97.	0.6	4
44	CTIM-13. PHASE 1 CLINICAL TRIAL OF ONCOLYTIC VIRAL IMMUNOTHERAPY WITH CAN-2409 + VALACYCLOVIR IN COMBINATION WITH NIVOLUMAB AND STANDARD OF CARE (SOC) IN NEWLY DIAGNOSED HIGH-GRADE GLIOMA (HGG). <i>Neuro-Oncology</i> , 2021, 23, vi52-vi52.	0.6	1
45	TAMI-35. DETECTING SINGLE-CELL INTERACTIONS IN ORGANOTYPIC CULTURES OF GLIOBLASTOMA USING BARCODED RABIES VIRUS. <i>Neuro-Oncology</i> , 2021, 23, vi205-vi205.	0.6	0
46	DDRE-18. THERAPEUTIC EFFECTS OF TASQUINIMOD ON GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2021, 23, vi78-vi78.	0.6	0
47	46. PAN-CANCER ANALYSIS OF ORTHOTOPIC PATIENT DERIVED XENOGRAFTS FROM BRAIN METASTASES. <i>Neuro-Oncology Advances</i> , 2020, 2, ii9-ii9.	0.4	0
48	Redesigned reporter gene for improved proton exchange-based molecular MRI contrast. <i>Scientific Reports</i> , 2020, 10, 20664.	1.6	12
49	HSV-1 Oncolytic Viruses from Bench to Bedside: An Overview of Current Clinical Trials. <i>Cancers</i> , 2020, 12, 3514.	1.7	38
50	Hypoxic Roadmap of Glioblastoma—Learning about Directions and Distances in the Brain Tumor Environment. <i>Cancers</i> , 2020, 12, 1213.	1.7	10
51	Cytomegalovirus Encephalopathy during Brain Tumor Irradiation. <i>Clinical Cancer Research</i> , 2020, 26, 3077-3078.	3.2	1
52	Immune Escape Mediated by Exosomal PD-L1 in Cancer. <i>Advanced Biology</i> , 2020, 4, e2000017.	3.0	19
53	A Platinum(IV) Prodrug—Perfluoroaryl Macrocyclic Peptide Conjugate Enhances Platinum Uptake in the Brain. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 6741-6747.	2.9	20
54	Tumor Interferon Signaling Is Regulated by a lncRNA INCR1 Transcribed from the PD-L1 Locus. <i>Molecular Cell</i> , 2020, 78, 1207-1223.e8.	4.5	43

#	ARTICLE	IF	CITATIONS
55	Extracellular Vesicles Induce Mesenchymal Transition and Therapeutic Resistance in Glioblastomas through NF- κ B/STAT3 Signaling. <i>Advanced Biology</i> , 2020, 4, 1900312.	3.0	15
56	FASN Is a Biomarker Enriched in Malignant Glioma-Derived Extracellular Vesicles. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1931.	1.8	20
57	Glioblastoma infiltration of both tumor- and virus-antigen specific cytotoxic T cells correlates with experimental virotherapy responses. <i>Scientific Reports</i> , 2020, 10, 5095.	1.6	28
58	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2020, 22, 1073-1113.	0.6	543
59	KLF4K409Q mutated meningiomas show enhanced hypoxia signaling and respond to mTORC1 inhibitor treatment. <i>Acta Neuropathologica Communications</i> , 2020, 8, 41.	2.4	25
60	Mechanisms and therapeutic implications of hypermutation in gliomas. <i>Nature</i> , 2020, 580, 517-523.	13.7	374
61	Final results of controlled IL-12 monotherapy in adults with grade III or IV gliomas.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3040-3040.	0.8	1
62	National Institute of Neurological Disorders and Stroke: current funding status, opportunities, challenges, emerging scientific advances, and recommendations for neurosurgery. <i>Journal of Neurosurgery</i> , 2020, 133, 1264-1269.	0.9	7
63	Controlled IL-12 in combination with a PD-1 inhibitor subjects with recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2510-2510.	0.8	3
64	Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	170
65	Letter: When Less is More: Dexamethasone Dosing for Brain Tumors. <i>Neurosurgery</i> , 2019, 85, E607-E608.	0.6	20
66	Frameless Stereotactic Navigation during Insular Glioma Resection using Fusion of Three-Dimensional Rotational Angiography and Magnetic Resonance Imaging. <i>World Neurosurgery</i> , 2019, 126, 322-330.	0.7	11
67	Proteomic Analysis Implicates Vimentin in Glioblastoma Cell Migration. <i>Cancers</i> , 2019, 11, 466.	1.7	24
68	Molecular responses to immune checkpoint blockade in glioblastoma. <i>Nature Medicine</i> , 2019, 25, 359-361.	15.2	35
69	Radiation-Induced Targeted Nanoparticle-Based Gene Delivery for Brain Tumor Therapy. <i>ACS Nano</i> , 2019, 13, 4028-4040.	7.3	147
70	Imaging flow cytometry facilitates multiparametric characterization of extracellular vesicles in malignant brain tumours. <i>Journal of Extracellular Vesicles</i> , 2019, 8, 1588555.	5.5	86
71	Pneumatosis Intestinalis After Molecular-Targeted Therapy. <i>World Neurosurgery</i> , 2019, 125, 312-315.	0.7	9
72	Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. <i>Nature</i> , 2019, 565, 234-239.	13.7	956

#	ARTICLE	IF	CITATIONS
73	Characterization of single microvesicles in plasma from glioblastoma patients. <i>Neuro-Oncology</i> , 2019, 21, 606-615.	0.6	72
74	An oncolytic herpesvirus expressing E-cadherin improves survival in mouse models of glioblastoma. <i>Nature Biotechnology</i> , 2019, 37, 45-54.	9.4	56
75	Viral and other therapies for recurrent glioblastoma: is a 24-month durable response unusual?. <i>Neuro-Oncology</i> , 2019, 21, 14-25.	0.6	69
76	The multiple protective roles and molecular mechanisms of melatonin and its precursor N-acetylserotonin in targeting brain injury and liver damage and in maintaining bone health. <i>Free Radical Biology and Medicine</i> , 2019, 130, 215-233.	1.3	59
77	Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy. <i>Clinical Cancer Research</i> , 2019, 25, 290-299.	3.2	88
78	Cytomegalovirus promotes murine glioblastoma growth via pericyte recruitment and angiogenesis. <i>Journal of Clinical Investigation</i> , 2019, 129, 1671-1683.	3.9	52
79	Evaluation of controlled IL-12 in combination with a PD-1 inhibitor in subjects with recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2020-2020.	0.8	4
80	Evaluation of controlled IL-12 as monotherapy in subjects with recurrent GBM.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2053-2053.	0.8	0
81	Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. <i>Science Advances</i> , 2018, 4, eaar2766.	4.7	416
82	Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 2574-2584.	3.2	40
83	Adult Tethered Cord Syndrome Following Chiari Decompression. <i>World Neurosurgery</i> , 2018, 112, 205-208.	0.7	6
84	Multiplexed Profiling of Single Extracellular Vesicles. <i>ACS Nano</i> , 2018, 12, 494-503.	7.3	256
85	Anticancer activity of osmium(VI) nitrido complexes in patient-derived glioblastoma initiating cells and in vivo mouse models. <i>Cancer Letters</i> , 2018, 416, 138-148.	3.2	29
86	Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells. <i>Scientific Reports</i> , 2018, 8, 208.	1.6	24
87	Endoscopic Endonasal Resection of a Suprasellar Pituitary Adenoma Mimicking Tuberculum Sellae Meningioma in a Patient with an Intrasellar Persistent Trigeminal Artery. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2018, 79, S285-S286.	0.4	0
88	Oncolytic viruses sensitize human tumor cells for NY-ESO-1 tumor antigen recognition by CD4+ effector T cells.. <i>Onc Immunology</i> , 2018, 7, e1407897.	2.1	22
89	DDIS-26. BTP-7, A NOVEL PEPTIDE FOR THERAPEUTIC TARGETING OF MALIGNANT BRAIN TUMORS. <i>Neuro-Oncology</i> , 2018, 20, vi74-vi74.	0.6	1
90	INNV-13. ALLELE: A CONSORTIUM FOR PROSPECTIVE GENOMICS AND FUNCTIONAL DIAGNOSTICS TO GUIDE PATIENT CARE AND TRIAL ANALYSIS IN NEWLY-DIAGNOSED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi140-vi141.	0.6	0

#	ARTICLE	IF	CITATIONS
91	TMOD-14. A PATIENT-DERIVED CANCER CELL LINE ATLAS OF PRIMARY AND METASTATIC CENTRAL NERVOUS SYSTEM TUMORS. <i>Neuro-Oncology</i> , 2018, 20, vi271-vi271.	0.6	0
92	ATIM-15. A PHASE 1 STUDY OF Ad-RTS-hIL-12 + VELEDIMEX IN ADULTS WITH RECURRENT GLIOBLASTOMA: DOSE DETERMINATION WITH UPDATED OVERALL SURVIVAL. <i>Neuro-Oncology</i> , 2018, 20, vi3-vi4.	0.6	2
93	IMMU-02. ONCOLYTIC HSV THERAPY ENHANCES GLIOBLASTOMA CONTROL VIA THE EXPANSION OF FUNCTIONAL TUMOR-SPECIFIC T CELLS AND MODULATION OF MYELOID CELL POPULATION. <i>Neuro-Oncology</i> , 2018, 20, vi121-vi121.	0.6	0
94	EXTH-53. IN VIVO QUANTITATIVE ANALYSIS OF ONCOLYTIC VIRUS-TUMOR KINETICS. <i>Neuro-Oncology</i> , 2018, 20, vi96-vi96.	0.6	0
95	ATIM-32. PERSONALIZED NEOANTIGEN-TARGETING VACCINE GENERATES ROBUST SYSTEMIC AND INTRATUMORAL T CELL RESPONSES IN GLIOBLASTOMA (GBM) PATIENTS. <i>Neuro-Oncology</i> , 2018, 20, vi8-vi8.	0.6	0
96	Immunotherapy for glioblastoma: going viral. <i>Nature Medicine</i> , 2018, 24, 1094-1096.	15.2	25
97	Viruses in cancer therapy “ from benchwarmers to quarterbacks. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 657-658.	12.5	17
98	Demonstration of anti-tumor immunity via intratumoral regulated platform ad-RTS-hIL-12 in advanced breast cancer and recurrent glioblastoma patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3038-3038.	0.8	1
99	ALLELE: A consortium for prospective genomics and functional diagnostics to guide patient care and trial analysis in newly-diagnosed glioblastoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2003-2003.	0.8	1
100	Dissecting inherent intratumor heterogeneity in patient-derived glioblastoma culture models. <i>Neuro-Oncology</i> , 2017, 19, now253.	0.6	35
101	MicroRNA Signatures and Molecular Subtypes of Glioblastoma: The Role of Extracellular Transfer. <i>Stem Cell Reports</i> , 2017, 8, 1497-1505.	2.3	58
102	MicroRNA-Mediated Dynamic Bidirectional Shift between the Subclasses of Glioblastoma Stem-like Cells. <i>Cell Reports</i> , 2017, 19, 2026-2032.	2.9	33
103	Blood-brain-barrier spheroids as an in vitro screening platform for brain-penetrating agents. <i>Nature Communications</i> , 2017, 8, 15623.	5.8	224
104	Perfluoroarene-Based Peptide Macrocycles to Enhance Penetration Across the Blood-Brain Barrier. <i>Journal of the American Chemical Society</i> , 2017, 139, 15628-15631.	6.6	60
105	Salvage re-irradiation for recurrent high-grade glioma and comparison to bevacizumab alone. <i>Journal of Neuro-Oncology</i> , 2017, 135, 581-591.	1.4	15
106	Oncolytic Viruses in Cancer Treatment. <i>JAMA Oncology</i> , 2017, 3, 841.	3.4	426
107	IMMU-12. THE HISTONE DEACETYLASE INHIBITOR VALPROIC ACID AUGMENTS THE SUSCEPTIBILITY OF ONCOLYTIC VIRUS-INFECTED GLIOBLASTOMA CELLS TO PD-1 BLOCKADE THERAPY. <i>Neuro-Oncology</i> , 2017, 19, vi115-vi115.	0.6	0
108	IMMU-10. EXPRESSION OF PD-L2, IN GLIOBLASTOMA; IMPLICATIONS AS A BIOMARKER FOR IMMUNOTHERAPY. <i>Neuro-Oncology</i> , 2017, 19, vi114-vi114.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Expanded phase I study of intratumoral Ad-RTS-hIL-12 plus oral veledimex: Tolerability and survival in recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2044-2044.	0.8	8
110	Immunotherapy for glioblastoma: on the sidelines or in the game?. <i>Discovery Medicine</i> , 2017, 24, 201-208.	0.5	31
111	A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases. <i>Oncotarget</i> , 2016, 7, 27764-27777.	0.8	188
112	Current State of Immune-Based Therapies for Glioblastoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e132-e139.	1.8	13
113	CBIO-12. SIX EXTRACELLULAR VESICLE RELATED GENES CAN EXPLAIN THE PRO-TUMORIGENIC BEHAVIOR OF HETEROGENEOUS HIGH GRADE GLIOMAS. <i>Neuro-Oncology</i> , 2016, 18, vi37-vi37.	0.6	0
114	BKM-120 (Buparlisib): A Phosphatidylinositol-3 Kinase Inhibitor with Anti-Invasive Properties in Glioblastoma. <i>Scientific Reports</i> , 2016, 6, 20189.	1.6	38
115	Extracellular Vesicles from High-Grade Glioma Exchange Diverse Pro-oncogenic Signals That Maintain Intratumoral Heterogeneity. <i>Cancer Research</i> , 2016, 76, 2876-2881.	0.4	85
116	Design of a Microfluidic Chip for Magnetic-Activated Sorting of One-Bead-One-Compound Libraries. <i>ACS Combinatorial Science</i> , 2016, 18, 271-278.	3.8	8
117	Glioma and microglia, a double entendre. <i>Nature Immunology</i> , 2016, 17, 1240-1242.	7.0	20
118	IMST-05. NOVEL CAR-T CELLS TARGETING THE EXTRACELLULAR MATRIX OF GLIOBLASTOMA INDUCE STRONG ANTI-TUMOR IMMUNE RESPONSE. <i>Neuro-Oncology</i> , 2016, 18, vi86-vi87.	0.6	0
119	The Long Non-coding RNA HIF1A-AS2 Facilitates the Maintenance of Mesenchymal Glioblastoma Stem-like Cells in Hypoxic Niches. <i>Cell Reports</i> , 2016, 15, 2500-2509.	2.9	156
120	Extracellular Vesicles and MicroRNAs: Their Role in Tumorigenicity and Therapy for Brain Tumors. <i>Cellular and Molecular Neurobiology</i> , 2016, 36, 361-376.	1.7	36
121	Experimental therapies. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2016, 134, 183-197.	1.0	22
122	Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma. <i>Neuro-Oncology</i> , 2016, 18, 1137-1145.	0.6	126
123	A vaccine from plant virus proteins. <i>Nature Nanotechnology</i> , 2016, 11, 214-215.	15.6	21
124	Effect of controlled intratumoral viral delivery of Ad-RTS-hIL-12 + oral veledimex in subjects with recurrent or progressive glioma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2052-2052.	0.8	2
125	ATPS-08DISCOVERY OF NOVEL GLIOMA-TARGETING PEPTIDES USING A HIGH-THROUGHPUT MICROFLUIDIC MAGNETIC-ACTIVATED SORTER. <i>Neuro-Oncology</i> , 2015, 17, v19.4-v19.	0.6	0
126	Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy. <i>Oncolytic Virotherapy</i> , 2015, 4, 183.	6.0	16

#	ARTICLE	IF	CITATIONS
127	A cross-talk network that facilitates tumor virotherapy. <i>Nature Medicine</i> , 2015, 21, 426-427.	15.2	1
128	Glucose-Based Regulation of miR-451/AMPK Signaling Depends on the OCT1 Transcription Factor. <i>Cell Reports</i> , 2015, 11, 902-909.	2.9	50
129	Skull Base Chordomas and Chondrosarcomas: A Population-Based Analysis. <i>World Neurosurgery</i> , 2015, 83, 468-470.	0.7	4
130	Extracranial growth of glioblastoma multiforme. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 1521-1523.	0.8	25
131	Potentiating oncolytic viral therapy through an understanding of the initial immune responses to oncolytic viral infection. <i>Current Opinion in Virology</i> , 2015, 13, 25-32.	2.6	19
132	ATPS-98MONITORING ONCOLYTIC HSV-1 WITH NON-INVASIVE BIOLUMINESCENCE. <i>Neuro-Oncology</i> , 2015, 17, v40.1-v40.	0.6	0
133	IMPS-21EFFECT OF rQNestin 34.5 ONCOLYTIC HERPES VIRUS ON IMMUNE CHECKPOINT GENE EXPRESSION IN GLIOBLASTOMA CELLS AND EVALUATION OF THERAPEUTIC EFFICACY. <i>Neuro-Oncology</i> , 2015, 17, v117.4-v118.	0.6	0
134	Awake Craniotomy and Intraoperative MRI for Maximal Safe Resection in a Case of an Extensive Left Frontal and Insular Low-grade Glioma: 3-Dimensional Operative Video. <i>Operative Neurosurgery</i> , 2015, 11, 578-578.	0.4	2
135	Interferon-stimulated Gene 15 (ISG15) and ISG15-linked Proteins Can Associate with Members of the Selective Autophagic Process, Histone Deacetylase 6 (HDAC6) and SQSTM1/p62. <i>Journal of Biological Chemistry</i> , 2015, 290, 1485-1495.	1.6	85
136	Hypofractionated Versus Standard Radiation Therapy With or Without Temozolomide for Older Glioblastoma Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 384-389.	0.4	46
137	Modeling Cytomegalovirus Infection in Mouse Tumor Models. <i>Frontiers in Oncology</i> , 2015, 5, 61.	1.3	2
138	CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells. <i>Scientific Reports</i> , 2015, 5, 11483.	1.6	270
139	Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 1344-1355.	0.6	40
140	Oncolytic Virus-Mediated Immunotherapy: A Combinatorial Approach for Cancer Treatment. <i>Journal of Clinical Oncology</i> , 2015, 33, 2812-2814.	0.8	36
141	Awake right hemisphere brain surgery. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 1921-1927.	0.8	6
142	TGF β 2 Treatment Enhances Glioblastoma Virotherapy by Inhibiting the Innate Immune Response. <i>Cancer Research</i> , 2015, 75, 5273-5282.	0.4	75
143	No Free Lunch: Secondary Neoplasms After Stereotactic Radiation. <i>World Neurosurgery</i> , 2015, 83, 330-331.	0.7	1
144	Academic Productivity in Today's Training Climate: A Fellowship's Impact. <i>World Neurosurgery</i> , 2015, 83, 328-329.	0.7	1

#	ARTICLE	IF	CITATIONS
145	Belonging to a networkâ€™ microRNAs, extracellular vesicles, and the glioblastoma microenvironment. <i>Neuro-Oncology</i> , 2015, 17, 652-662.	0.6	78
146	MicroRNA-10b inhibition reduces E2F1-mediated transcription and miR-15/16 activity in glioblastoma. <i>Oncotarget</i> , 2015, 6, 3770-3783.	0.8	42
147	Response to energy depletion: miR-451/AMPK loop. <i>Oncotarget</i> , 2015, 6, 17851-17852.	0.8	7
148	Modulation of Natural Killer Cell Activity in the Setting of Oncolytic Virotherapy and with a Chimeric Antigen Receptor. <i>Blood</i> , 2015, 126, 210-210.	0.6	1
149	One size should not fit all: advancing toward personalized glioblastoma therapy. <i>Discovery Medicine</i> , 2015, 19, 471-7.	0.5	13
150	Phase 1 Clinical Trial of Intratumoral Reovirus Infusion for the Treatment of Recurrent Malignant Gliomas in Adults. <i>Molecular Therapy</i> , 2014, 22, 1056-1062.	3.7	119
151	Targeting Glioblastoma Invasion with GSK-3 inhibitors: Rapid Effects on the EMT Marker Vimentin. <i>Canadian Journal of Neurological Sciences</i> , 2014, 41, S1-S2.	0.3	0
152	Predicting Outcomes: Recursive Partitioning Analysis (RPA) Prognostic Algorithm for Patients with Metastatic Sarcoma to the Brain. <i>World Neurosurgery</i> , 2014, 82, 1030-1032.	0.7	0
153	How Much Is Enough? The Question of Extent of Resection in Glioblastoma Multiforme. <i>World Neurosurgery</i> , 2014, 82, e109-e110.	0.7	15
154	Low-Grade Gliomas and Quality of Life. <i>World Neurosurgery</i> , 2014, 82, e133-e134.	0.7	2
155	Developmental expression of GPR3 in rodent cerebellar granule neurons is associated with cell survival and protects neurons from various apoptotic stimuli. <i>Neurobiology of Disease</i> , 2014, 68, 215-227.	2.1	31
156	From Localization to Pathways: The Continuing Evolution of Diffusion Tensor Imaging. <i>World Neurosurgery</i> , 2014, 82, e47-e48.	0.7	6
157	Immunotherapy advances for glioblastoma. <i>Neuro-Oncology</i> , 2014, 16, 1441-1458.	0.6	164
158	Oncolytic Viruses and Their Application to Cancer Immunotherapy. <i>Cancer Immunology Research</i> , 2014, 2, 295-300.	1.6	308
159	Who Benefits from Surgery for Brain Metastases?. <i>World Neurosurgery</i> , 2014, 82, e115-e116.	0.7	0
160	Neoplasm Development After Stereotactic Radiosurgery for Arteriovenous Malformations. <i>World Neurosurgery</i> , 2014, 82, 304-306.	0.7	2
161	Image-Guided Maximal Resection of Intrinsic Tumors. <i>World Neurosurgery</i> , 2014, 82, 604-605.	0.7	1
162	Extracellular Vesicles Modulate the Glioblastoma Microenvironment via a Tumor Suppression Signaling Network Directed by miR-1. <i>Cancer Research</i> , 2014, 74, 738-750.	0.4	197

#	ARTICLE	IF	CITATIONS
163	Hypofractionated (HRT) versus standard (SRT) radiotherapy with or without temozolomide (T) for elderly patients with glioblastoma (GBM).. Journal of Clinical Oncology, 2014, 32, 2065-2065.	0.8	1
164	Ascending dose trials of a retroviral replicating vector (Toca 511) in patients with recurrent high-grade glioma.. Journal of Clinical Oncology, 2014, 32, 3078-3078.	0.8	0
165	NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nature Medicine, 2012, 18, 1827-1834.	15.2	164
166	Tannous et al. Respond:. Molecular Therapy, 2009, 17, 1311-1312.	3.7	1
167	A Phase I Trial of Ad.hIFN- β Gene Therapy for Glioma. Molecular Therapy, 2008, 16, 618-626.	3.7	114
168	The host response to cancer virotherapy. Current Opinion in Molecular Therapeutics, 2008, 10, 38-45.	2.8	46
169	Neurosurgical robotics: a review of brain and spine applications. Journal of Robotic Surgery, 2007, 1, 39-43.	1.0	38
170	A Phase I Open-Label, Dose-Escalation, Multi-Institutional Trial of Injection with an E1B-Attenuated Adenovirus, ONYX-015, into the Peritumoral Region of Recurrent Malignant Gliomas, in the Adjuvant Setting. Molecular Therapy, 2004, 10, 958-966.	3.7	401
171	Neurosurgical Delivery of Chemotherapeutics, Targeted Toxins, Genetic and Viral Therapies in Neuro-Oncology. Journal of Neuro-Oncology, 2004, 69, 101-117.	1.4	50
172	Guided genes for tumor warfare. Nature Biotechnology, 2002, 20, 235-236.	9.4	4
173	In vivo magnetic resonance imaging of transgene expression. Nature Medicine, 2000, 6, 351-354.	15.2	811
174	Cytotoxicity, apoptosis, and viral replication in tumor cells treated with oncolytic ribonucleotide reductase-defective herpes simplex type 1 virus (hrR3) combined with ionizing radiation. Cancer Gene Therapy, 2000, 7, 1051-1059.	2.2	48
175	Multicolumn Infusion of Gene Therapy Cells into Human Brain Tumors: Technical Report. Neurosurgery, 2000, 46, 663-669.	0.6	19
176	Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nature Medicine, 1999, 5, 881-887.	15.2	309
177	An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nature Biotechnology, 1998, 16, 444-448.	9.4	167
178	Gene Therapy for Brain Tumors. Brain Pathology, 1995, 5, 345-381.	2.1	93
179	Deep Sylvian Fissure Meningioma without Dural Attachment in an Adult. Neurosurgery, 1994, 35, 944-946.	0.6	28
180	The Current State of Glioma Data Registries. Neuro-Oncology Advances, 0, , .	0.4	1